

## OD-OS developing new diagnose and therapy device for the treatment of retinal disorders

### MIG AG and BC Brandenburg Capital GmbH to fund new technology approach in the field of ophthalmology

**Teltow/Potsdam.** OD-OS, a medical technology manufacturer outsourced in early 2008 from SensoMotoric Instruments GmbH (SMI), has developed with its NAVILAS diagnose and therapy device a new product that, in comparison to conventional methods used, makes much easier the diagnosing and laser treatment especially of retinal disorders caused by diabetes. Here the company which is based in Teltow relies on a new device approach combining the diagnose as well as the therapy function in a single unit and allowing, for the first time, navigation of therapy measures on the retina. MIG AG from Munich and BC Brandenburg Capital are supporting the firm by providing venture capital, funding in such a way the development and marketing of devices made by OD-OS. In the Brandenburg State, such investments are made through BFB Beteiligungsfonds Brandenburg by using funds provided by the European Regional Development Fund (EFRE) and by the Brandenburg state government. Such funding is meant to guarantee market introduction of the new device still in 2009.

"OD-OS stands for safe retina navigation and treatment. Using the latest image processing methods, the practising doctor is now in a position to administer safe, accurate and time-saving treatment", says **Dr. Winfried Teiwes**, managing director of OD-OS, underlining the usefulness of the device for doctors and patients. "Thus, OD-OS allows to reach higher standards for the treatment of retinal disorders, which are characterized by greater safety, greater accuracy, by increased effectiveness and by less time being required", **Dr. Teiwes** points out.

"We are glad to have as partners MIG AG and BC Brandenburg Capital GmbH, who are financially strong investors with an entrepreneurial mind-set. Last year, an outstanding team was brought together at OD-OS, and

ground-breaking technological developments were brought under way", says **Eberhard Schmidt**, managing director of SensoMotoric Instruments GmbH. "With funding having now commenced, OD-OS is having in hard times the resources required and can focus in the first place on developing potentials in the field of retinal therapy", he says, underlining the importance of such funds for OD-OS.

Michael Motschmann, chief executive of MIG AG, underlines the product's medical as well as commercial advantages: "Thanks to its process sequence and retina imaging, NAVILAS allows for greater transparency during therapy, thus opening new approaches for therapy and training." Moreover, the practising doctor is able to increase the throughput of changes and can provide greater quality of treatment at the same time."

"The bringing in of core competence in the fields of high-speed image processing, camera development, system integration and man-machine interfaces could lead, from the points of view of investors, to an innovative boost in the design of devices," confirms **Thomas Krause**, senior manager in charge of the investment by BC Brandenburg Capital GmbH. "The technological progress, as is generated by such development, will lead to safer treatment, greater accuracy, and will to time being saved by the practising doctor due to process orientation, **Krause** adds."

### About OD-OS GmbH

OD-OS GmbH ([www.od-os.com](http://www.od-os.com)) was founded in Teltow in early 2008 as a subsidiary of SensoMotoric Instruments GmbH. Object of the company is development and marketing of medical technology focussing on ophthalmology. The products are used, in particular, for treatment of retinal disorders, the causes of which can be found in clinical syndromes of diabetic retinopathy as well as age-related macula degeneration (AMD) which lead to blindness. With its combined NAVILAS therapy & diagnose device, the team of Dr. Teiwes, which has great experience in the medical sector, has put into reality an innovative technological approach that leads to improved treatment of retinal disorders thanks to

**06.03.2009**

---

combining imaging processes and laser technology in a single unit.

## **About MIG AG**

MIG Verwaltungs AG is one of Germany's most active venture capital companies. It is based in Munich and has already invested in over 20 innovative firms in Germany and Austria. MIG Verwaltungs AG is the initiator or management company for the MIG Fund with a total capital volume of more than 200mln Euro distributed exclusively by AWAG and addressed exclusively to private investors. You will find more detailed information on MIG Verwaltungs AG, the MIG Fund and its investment portfolio under [www.mig-fonds.de](http://www.mig-fonds.de) and [www.mig.ag](http://www.mig.ag).

## **About BC Brandenburg Capital GmbH**

BC Brandenburg Capital GmbH (BC GmbH) operates as a management and a holding company for various affiliated funds. Being a subsidiary of InvestitionsBank des Landes Brandenburg (ILB), and being affiliated to tbG Technologie-Beteiligungs-Gesellschaft mbH of KfW Mittelstandsbank, BC GmbH supports growth-oriented and innovative medium-size companies in financing all phases of enterprise development: from research to product or process development, to market introduction as well as a possible introduction of the company to the stock exchange.

Currently, BC GmbH manages 5 funds equipped with a total capital volume of 140mln Euro.

Currently, BC GmbH acts as the funding partner for more than 40 active enterprises. As part of ZukunftsAgentur Brandenburg, as well as in combination with private capital investors, the funds administered by BC Brandenburg Capital have, in almost 15 years of business activity, taken stakes with an overall volume exceeding 100mln Euro. Its investment activities have focussed on companies related to information and communication technology, Life Sciences, nano-technology, testing & measuring technology, microelectronics, as well as industrial and process technology. You will find more detailed information under [www.bc-capital.de](http://www.bc-capital.de).

## **About the BFB BeteiligungsFonds Brandenburg**

BFB BeteiligungsFonds Brandenburg GmbH

(BFB) was established by: InvestitionsBank des Landes Brandenburg, in October 2005 by order of the Ministry for the Economy, and its capital volume is 30mln Euro. The active phase of investment was concluded in late 2008 according to schedule. The aim of the Fund was to provide, in particular, small- and medium-size companies in Brandenburg during their start-up or expansion stage with capital of up to 1.5mln Euro through dormant or open partnership. 75pc of the means of the BFB Fund were provided by the European Regional Development Fund (EFRE), and 25pc were brought up by the Brandenburg State Ministry for the Economy. Management was handed over to BC Brandenburg Capital GmbH. You will find more detailed information under: [www.ilb.de](http://www.ilb.de).

## **About SensoMotoric Instruments Gesellschaft für innovative Sensorik mbH (SMI)**

SMI ([www.smivision.com](http://www.smivision.com)) has been active in the field of Computer Vision and image processing. SMI develops and sells measuring equipment and solutions particularly for applications related to the human eye and brain in the fields of ergonomics, market research, man-machine interaction as well as science and medical technology. SMI serves clients worldwide from locations in Teltow near Berlin, Germany, and Boston, USA, as well as through distribution partners in Europe and Asia. SMI's core competences are in the fields of high-speed image processing, camera development, system design, and in developing devices and application software. Established in 1991, SMI has become one of the leading suppliers worldwide for equipment to measure eye movements and lines of view.

Pressekontakt:  
BC Brandenburg Capital GmbH  
ILB-/Pressesprecher: Matthias Haensch  
Tel.: 0331 660-1505  
Fax: 0331 660-1231  
E-Mail: [presse@ilb.de](mailto:presse@ilb.de)